CINRYZE® (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks in children (6 years of age and older), teenagers and adults with Hereditary Angioedema (HAE).
OnePath is a free product support program that can help eligible patients who have been prescribed CINRYZE per the approved indication gain access to their medication. Once CINRYZE® (C1 esterase inhibitor [human]) has been prescribed to you and you have enrolled in OnePath, you will be connected with a dedicated Patient Support Manager (PSM) who will work with you to help you get access to your medication, in addition to providing other product support services.
Help with facilitating an insurance benefits investigation, and explaining insurance coverage and financial assistance options (if applicable)
In-home administration training and support for you and your caregiver(s) at no cost
Educational resources and the OnePath Mobile App for you and your caregiver(s) at no cost
Resources specifically tailored for caregivers to give them the information and support needed to make informed decisions about the health of those they care for
Patients enrolled in OnePath may use the OnePath Mobile App to connect with OnePath and track their health in a personal eDiary.
Do not try to self-administer CINRYZE until a healthcare professional has taught you or a caregiver how.
Are you ready to learn how to self-administer?
Learn more about the Path to Independence™ Program.
You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product.
Tell your healthcare provider about all of your medical conditions, including if you have an indwelling catheter/access device in one of your veins; have a history of blood clots, heart disease, or stroke; or are taking birth control pills or androgens. Also tell your healthcare provider if you are pregnant or planning to become pregnant, or are breastfeeding or planning to breastfeed. It is not known if CINRYZE can harm your unborn baby, or if CINRYZE passes into your milk and if it can harm your baby.
Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, turning blue (look at lips and gums), fast heartbeat, swelling of the face, faintness, rash, hives.
Serious blood clots may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid heart rate, numbness or weakness on one side of the body.
Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
The most common side effects seen with CINRYZE were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional safety information, please click here for Full Prescribing Information and discuss with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA.